AZ's MedImmune gets cell-line patent; Novartis' Bexsero nabs innovation prize;

> AstraZeneca's ($AZN) MedImmune has received a U.S. patent for an optimized cell line used in flu vaccine production. Report

> Novartis' ($NVS) meningitis B vaccine, Bexsero, has won the U.K.'s Prix Galien innovation prize. Report

> Takeda has invested an undisclosed amount in Vaccine Safe Co. and will assist in the adoption of its vaccination management system. Release

> A team of New Zealand researchers has discovered new vaccine technology that can be used to treat asthma and other allergic diseases. Report

> After a U.S. visit from Indian Prime Minister Narendra Modi, the U.S. and India have agreed to collaborate on the development of affordable vaccines to fight dengue, malaria and tuberculosis. More

And Finally... Tracking children with fingerprint technology could improve vaccine accuracy, Michigan State University researchers say. More

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.